| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| HUNT DOUGLAS M | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES | /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt | 20 Feb 2026 | 0001727172 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PBYI | Common Stock | Award | $0 | +49,394 | +32% | $0.000000 | 205,301 | 18 Feb 2026 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PBYI | Stock Option (Right to Buy) | Award | $0 | +70,321 | $0.000000 | 70,321 | 18 Feb 2026 | Common Stock | 70,321 | $6.68 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date. |
| F2 | Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date. |
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.